Kezar Life Sciences Overview
- Founded
-
2015

- Status
-
Public
- Employees
-
56

- Stock Symbol
-
KZR

- Share Price
-
$7.31
- (As of Thursday Closing)
Kezar Life Sciences General Information
Description
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.
Contact Information
- 4000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Kezar Life Sciences Timeline
Kezar Life Sciences Stock Performance
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$7.31 | $6.90 | $4.30 - $18.55 | $501M | 68.5M | 661K | -$1.01 |
Kezar Life Sciences Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 295,394 | 773,406 | 97,265 | (1,918) |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (63,538) | (53,149) | (41,406) | (36,041) |
Net Income | (64,270) | (54,630) | (41,742) | (35,087) |
Total Assets | 304,770 | 217,933 | 151,842 | 89,513 |
Total Debt | 13,316 | 14,044 | 5,464 | 6,364 |
Kezar Life Sciences Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Kezar Life Sciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Kezar Life Sciences Comparisons
Industry
Financing
Details
Kezar Life Sciences Competitors (61)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
AVEO Oncology | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000&0 | 00000 |
0000000 | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 000000000 | 00000 |
0000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
Kezar Life Sciences Patents
Kezar Life Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020228307-A1 | Thiazole derivatives as protein secretion inhibitors | Pending | 28-Feb-2019 | 0000000000 | |
CA-3131930-A1 | Thiazole derivatives as protein secretion inhibitors | Pending | 28-Feb-2019 | 0000000000 | |
EP-3930849-A1 | Thiazole derivatives as protein secretion inhibitors | Pending | 28-Feb-2019 | 0000000000 | |
JP-2022522014-A | Thiazole derivative as a protein secretion inhibitor | Pending | 28-Feb-2019 | 0000000000 | |
US-20220153732-A1 | Protein secretion inhibitors | Pending | 28-Feb-2019 | C07D417/14 |
Kezar Life Sciences Executive Team (9)
Kezar Life Sciences Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Christopher Kirk Ph.D | Kezar Life Sciences | Chief Scientific Officer & Board Member | 000 0000 |
Elizabeth Garner | Self | Board Member | 000 0000 |
Franklin Berger | Self | Board Member | 000 0000 |
Graham Cooper | Self | Chairman & Board Member | 000 0000 |
John Fowler | Kezar Life Sciences | Chief Executive Officer & Board Member | 000 0000 |
Kezar Life Sciences Signals
Kezar Life Sciences Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Kezar Life Sciences ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
23.99 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile

Biotechnology
Subindustry
00 of 465
Rank
Percentile
